written on 01.05.2014

Novo, Teva, Shire, Actavis and Mylan post Q1 growth as Endo gets pummeled


Earnings were kind to many of pharma's midsize players between Wednesday and Thursday, with several drugmakers–Endo excluded–posting growth. But not all of those companies reaped the sales they expected to, with Novo Nordisk and Teva falling into that category. Big changes may be in store, however, at least for a few of them–Shire and Mylan, for two, may soon find themselves in the middle of pharma's recent M&A storm.